SB-2343

N/A

Report date: 2022/07/19 16:22:54

NME

Base Information

Drug NameSB-2343

Drug Alias NameVS-5584SB-2312SB-2343

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitorsPhosphatidylinositol 3 kinase delta inhibitorsPhosphatidylinositol 3 kinase gamma inhibitors +[6]

TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2Phosphatidylinositol 3 kinase beta +[6]

Therapy Area/IndicationsNeoplasm MetastasisLymphomaNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSyncore Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesVerastem Inc

Active IndicationsN/A

Inactive IndicationsNeoplasm MetastasisLymphomaNeoplasms

Other Information

ATC CodeN/A